Advertisement

Cyclin D1 Expression in Vestibular Schwannoma

  • Luis Lassaletta
  • Laura Del Río
  • Mercedes Patrón
  • Miguel Torres
  • Agueda Díaz-Anadón
  • Jose M. Roda
  • Javier Gavilan
  • Juan A. Rey
Chapter
Part of the Tumors of the Central Nervous System book series (TCNS, volume 7)

Abstract

Recent studies suggest a role for cyclin D1 in Schwann cell differentiation. The purpose of the study was to evaluate the relationship between cyclin D1 expression and clinical and histological features of vestibular schwannoma. Twenty-one vestibular schwannoma specimens were examined. Immunohistochemistry analysis was performed with anticyclin D1. Clinical charts, audiometric data, and MRI characteristics were reviewed as well as histological features. Cyclin D1 expression was found in 52% of cases. Cyclin D1 expression was more frequent in right sided tumors (p = 0.02), and in tumors with nuclear degenerative changes (p < 0.0001). Cyclin D1 expression, present in nearly half of the cases, may play a role in the development of these tumors. Further studies are needed to fully understand the contributions of histopathological and immunohistochemical factors to vestibular schwannoma biological activity.

Keywords

Schwann Cell Mantle Cell Lymphoma Malignant Mesothelioma Vestibular Schwannoma Vestibular Schwannomas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bello MJ, Martinez-Glez V, Franco-Hernandez C, Pefla-Granero C, de Campos JM, Isla A, Lassaletta L, Vaquero J, Rey JA (2007) DNA methylation pattern in 16 tumor-related genes in schwannomas. Cancer Genet Cytogenet 172:84–86PubMedCrossRefGoogle Scholar
  2. Caye-Thomasen P, Werther K, Nalla A, Bøg-Hansen TC, Nielsen HJ, Stangerup SE, Thomsen J (2005) VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26:98–101PubMedCrossRefGoogle Scholar
  3. Coqueret O (2002) Linking cyclins to transcriptional ­control. Gene 299:35–55PubMedCrossRefGoogle Scholar
  4. Del Río L, Lassaletta L, Alfonso C, Sarriá MJ, Gavilán J (2006) Clinical tumoral size dissociation in acoustic neuroma: reality or measure distortion? Acta Otorrinolaringol Esp 57:345–349PubMedGoogle Scholar
  5. Donnellan R, Chetty R (1998) Cyclin D1 and human ­neoplasia. Mol Pathol 51:1–7PubMedCrossRefGoogle Scholar
  6. Gomez-Brouchet A, Delisle MB, Cognard C, Bonafe A, Charlet JP, Deguine O, Fraysse B (2001) Vestibular schwannomas: correlations between magnetic resonance imaging and histopathologic appearance. Otol Neurotol 22:79–86PubMedCrossRefGoogle Scholar
  7. Herwadker A, Vokurka EA, Evans DG, Ramsden RT, Jackson A (2005) Size and growth rate of sporadic vestibular schwannoma: predictive value of ­information available at presentation. Otol Neurotol 26:86–92PubMedCrossRefGoogle Scholar
  8. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25:1620–1628PubMedCrossRefGoogle Scholar
  9. Lasak JM, Welling DB, Akhmametyeva EM, Salloum M, Chang LS (2002) Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 112:1555–1561PubMedCrossRefGoogle Scholar
  10. Lassaletta L, Bello MJ, Del Rio L, Alfonso C, Roda JM, Rey JA, Gavilan J (2006) DNA methylation of multiple genes in vestibular schwannoma: relationship with clinical and radiological findings. Otol Neurotol 27:1180–1185PubMedCrossRefGoogle Scholar
  11. Lassaletta L, Patrón M, Del Río L, Alfonso C, Roda JM, Rey JA, Gavilan J (2007a) Cyclin D1 expression and histopathologic features in vestibular schwannomas. Otol Neurotol 28:939–941PubMedCrossRefGoogle Scholar
  12. Lassaletta L, Patrón M, González T, Martinez-Glez V, Rey JA, Gavilan J (2007b) RASSF1A methylation and cyclin D1 expression in vestibular schwannomas. Acta Neuropathol 114:431–433PubMedCrossRefGoogle Scholar
  13. Lü J, Zou J, Wu H, Cai L (2008) Compensative shuttling of merlin to phosphorylation on serine 518 in vestibular schwannoma. Laryngoscope 118:169–174PubMedCrossRefGoogle Scholar
  14. Mohyuddin A, Neary WJ, Wallace A, Wu CL, Purcell S, Reid H, Ramsden RT, Read A, Black G, Evans DG (2002) Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 39:315–322PubMedCrossRefGoogle Scholar
  15. Neff BA, Oberstien E, Lorenz M, Chaudhury AR, Welling DB, Chang LS (2006) Cyclin D(1) and D(3) expression in vestibular schwannomas. Laryngoscope 116:423–426PubMedCrossRefGoogle Scholar
  16. Seol HJ, Jung HW, Park SH, Hwang SK, Kim DG, Paek SH, Chung YS, Sub LC (2005) Aggressive vestibular schwannomas showing postoperative rapid growth – their association with decreased p27 expression. J Neurooncol 75:203–207PubMedCrossRefGoogle Scholar
  17. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR (2005) The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 25:2384–2394PubMedCrossRefGoogle Scholar
  18. Yokoo H, Arai H, Isoda K, Arai M, Sasaki A, Hirato J, Nakazato Y (2003) Characterization of eosinophilic hyaline droplets in schwannoma. Acta Neuropathol (Berl) 105:170–176Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Luis Lassaletta
    • 1
  • Laura Del Río
    • 1
  • Mercedes Patrón
    • 1
  • Miguel Torres
    • 1
  • Agueda Díaz-Anadón
    • 1
  • Jose M. Roda
    • 1
  • Javier Gavilan
    • 1
  • Juan A. Rey
    • 1
  1. 1.Department of Otolaryngology, Laboratorio Oncogenetica MolecularLa Paz University HospitalMadridSpain

Personalised recommendations